
    
      Several recent clinical trials have demonstrated that angiotensin II receptor blockers (ARBs)
      have cardiovascular as well as renal protective effects. However, it is a problem that the
      number of Asian patients is very little in these trials. The researchers examine the
      treatment meaning by ARB about the prognosis of the patient who amalgamates either among high
      blood pressure, the ischemic heart disease, and congestive heart failures.
    
  